Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review Ppublish 20 citations
PubMed: 33711512 DOI: 10.1016/j.trsl.2021.03.007
Pain in sickle cell disease: current and potential translational therapies.
Transl Res 234:141-158
Authors: Varun Sagi, Aditya Mittal, Huy Tran, Kalpna Gupta
Affiliations
- School of Medicine, University of Minnesota, Minneapolis, Minnesota.
- School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.
- School of Medicine, Kansas City University, Joplin, Missouri.
- Hematology/Oncology, Department of Medicine, University of California, Irvine and Southern California Institute for Research and Education, VA Medical Center, Long Beach, California.
Abstract
Pain is a major comorbidity of sickle cell disease (SCD). Patients with SCD may suffer from both acute and chronic pain. Acute pain is caused by recurrent and unpredictable episodes of vaso-occlusive crises (VOC), whereas the exact etiology of chronic pain is still unknown. Opioids are the mainstay for pain treatment, but the opioid epidemic has significantly altered access to prescription opioids and has brought concerns over their long-term use into the forefront, which have negatively impacted the treatment of sickle pain. Opioids remain potent analgesics but growing opioid-phobia has led to the realization of an unmet need to develop nonopioid therapies that can provide relief for severe sickle pain. This realization has contributed to the approval of 3 different drugs by the Food and Drug Administration (FDA) for the treatment of SCD, particularly to reduce VOC and/or have an impact on the pathobiology of SCD. In this review, we outline the challenges and need for validation of side-effects of opioids and provide an update on the development of mechanism-based translational therapies, specifically targeting pain in SCD.
MeSH
Cells, Chronic Pain, Anemia, Sickle Cell, Pain, Pharmaceutical Preparations, Clinical Laboratory Techniques, Acute Pain, Therapeutics
Cited by
- Differential clinical characteristics across traditional Chinese medicine (TCM) Syndromes in patients with sickle cell disease. Front Pain Res (Lausanne), 2024
- Can we use biomarkers to identify those at risk of acute pain from sickle cell disease? Expert Rev Hematol, 2024
- Adolescents' perspectives on non-pharmacological pain interventions for sickle cell crisis management: A population-based survey. PLoS One, 2025
- The Associations Between Opioid Use Disorder and Healthcare-Related Outcomes in Vaso-occlusive Crisis. J Gen Intern Med, 2024
- Unmet Need: Mechanistic and Translational Studies of Sickle Cell Disease Pain as a Whole-Person Health Challenge. J Pain, 2024
- Digital cognitive behavioral therapy vs education for pain in adults with sickle cell disease. Blood Adv, 2024
- Pain mechanisms in sickle cell disease. Are we closer to a breakthrough? Haematologica, 2023
- Endoplasmic Reticulum Stress in Chemotherapy-Induced Peripheral Neuropathy: Emerging Role of Phytochemicals. Antioxidants (Basel), 2022
- Gut microbiota dysbiosis alters chronic pain behaviors in a humanized transgenic mouse model of sickle cell disease. Pain, 2024
- Inflammation and autoimmunity are interrelated in patients with sickle cell disease at a steady-state condition: implications for vaso-occlusive crisis, pain, and sensory sensitivity. Front Immunol, 2024